|
Written by bioXplorer
|
-
Fda responds to astrazeneca’s citizen petition -- fda also grants approval for a generic version of pulmicort respules
On 18 November 2008, the US FDA responded to AstraZeneca's Citizen Petition surrounding the company's concern about the approval of any generic version of PULMICORT RESPULES® (budesonide inhalation suspension). While the FDA agreed with some of the company's concerns, other arguments in the Citizen Petition were denied. (Source: AstraZeneca) MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
-
Phase iii studies show that vandetanib (zactima) brings clinical benefits to patients with lung cancer
AstraZeneca today announced results from three Phase III studies of ZACTIMA (vandetanib) in combination with chemotherapy agents docetaxel (ZODIAC) and pemetrexed (ZEAL) and as monotherapy (ZEST) in non-small cell lung cancer (NSCLC). (Source: AstraZeneca)
-
Astrazeneca enters agreement for authorized generic pulmicort respules
AstraZeneca today announced that it has entered into a supply and distribution agreement with Par Pharmaceutical to distribute an authorized generic version of budesonide inhalation suspension in the United States in response to the launch ‘at risk’ of a generic version of this product by Teva. Currently, the authorized generic product will be distributed in the 0.25 mg/2 mL and 0.5 mg/2 mL dosage strengths. Par Pharmaceutical began shipping the product today. (Source: AstraZeneca)
-
Medtronic spine device faces probe
The off-label use of a Medtronic implant for promoting bone growth is being investigated amid an FDA warning and whistleblowers' lawsuits. (Source: WSJ.com: Health)
-
Novartis highlights innovative approach to drug discovery with dynamic advance in exploratory pipeline
(Source: Novartis International AG)
-
Industry leaders weigh in on likely changes to the health plan industry under the obama administration and new congress
Health Plan Week provides an in-depth analysis of potential changes to the health plan industry and their possible effect on health plans' bottom lines. (PRWeb Nov 17, 2008)
Read the full story at http://www.prweb.com/releases/2008/11/prweb1612554.htm (Source: PRWeb: Medical Pharmaceuticals) MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
-
Hepatitis c therapeutic dna vaccine delivered by inovio biomedical's electroporation technology reduces viral load by up to 99.7% : clinical data presented at annual scientific meeting of the american association for the study of liver diseases
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported positive additional interim results from its ongoing phase I/II clinical study of its therapeutic DNA vaccine against hepatitis C virus (HCV). This vaccine is being delivered using Inovio’s electroporation-based DNA delivery system. In the third and highest dose cohort of the study, two of three subjects demonstrated reductions in viral load of 93% and 99.7%. Previously reported middle dose cohort results demonstrated an 87% and 98% reduction in HCV in two of three subjects, while no anti-viral effect was observed in the low dose cohort. No safety issues have been noted to date in the trial. Thes...
-
Drug information association (dia) opens new office in china
The Drug Information Association (DIA), the premier, multidisciplinary, non-profit association that provides a neutral forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes, has opened an office in Beijing, China. (PRWeb Nov 18, 2008)
Read the full story at http://www.prweb.com/releases/Drug_Information/Association/prweb1634784.htm (Source: PRWeb: Medical Pharmaceuticals)
-
M2s, inc. achieves milestone with 150,000th radiographic scan for evaluation and surveillance of aortic aneurysms
M2S Inc., an industry leader in endovascular treatment planning and patient registries, announced today that the company has reached a new milestone, having processed over 150,000 radiographic scans for evaluation and surveillance of aortic aneurysms. With each scan received, M2S evaluates approximately 1,000 images, pushing M2S' total images received and processed to over 150 million. (PRWeb Nov 18, 2008)
Read the full story at http://www.prweb.com/releases/endovascular/imaging/prweb1631214.htm (Source: PRWeb: Medical Pharmaceuticals)
-
Threat of debt write-offs at mccarthy & stone
Lenders to McCarthy & Stone, the retirement-home builder, may have to write off nearly half of the company's debt if third-party investors are not found to put up new... (Source: FT.com - Drugs and Healthcare)
|
|
|
<< Start < Previous 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 5 - 5 of 10 |
Latest News 
